Detection of CK20mRNA in peripheral blood of pancreatic cancer and its clinical significance.
OBJECTIVE
To detect the expression of CK20mRNA in peripheral blood of pancreatic cancer and evaluate its clinical significance.


METHODS
Expression of CK20mRNA in peripheral blood was detected by fluorogenic qualitative reverse transcription-polymerase chain reaction (RT-PCR) in 40 cases of pancreatic cancer at the night before operation, in 5 cases of benign pancreatic diseases, in 5 cases of healthy individuals. The relationships were investigated between CK20mRNA expression and the clinicopathological variables, and clinical follow-up outcome in those patients with pancreatic cancer having undergone radical resection.


RESULTS
Of the 40 patients with pancreatic cancer, 23 (57.5%) cases were positive for CK20mRNA expression. CK20mRNA expression was significantly correlated with lymphatic metastasis (P = 0.008), histopathological grading (P = 0.009), and pathological stage (P = 0.021); there was no significant correlation between CK20mRNA expression and age, gender, tumor diameter, and depth of invasion. The cumulative metastasis rates of patients with CK20mRNA expression were higher than those of patients with no CK20mRNA expression within 6 mo (34.7% vs 5.9%, P = 0.043) or 12 mo (73.9% vs 35.3%, P = 0.02) after operation. CK20mRNA expression in peripheral blood of pancreatic cancer indicated poorer prognosis. The survival rate of patients with CK20mRNA expression was lower than that of patients with negative CK20mRNA expression (Log-Rank = 13.31, P = 0.0003).


CONCLUSIONS
CK20mRNA is a sensitive and specific molecular marker for the detection of micrometastasis in peripheral blood of patients with pancreatic cancer. The CK20mRNA expression in peripheral blood is correlated with biological characteristic of pancreatic cancer. It can help to predict the prognosis of pancreatic cancer after operation, and to determine which patient will benefit from aggressive adjuvant therapies.
Zhang
Yun-Li
YL
Department of Hepato-Pancreatico-Billiary Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China. zylzrl@mail.hz.zj.cn
Feng
Jian-Guo
JG
Gou
Jian-Min
JM
Zhou
Li-Xin
LX
Wang
Ping
P
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007381:Intermediate Filament Proteins / Q000235:genetics*; D053554:Keratin-20; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D011379:Prognosis; D012333:RNA, Messenger / Q000097:blood; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D007381:Intermediate Filament Proteins; C507499:KRT20 protein, human; D053554:Keratin-20; D012333:RNA, Messenger
J Virol Methods. 2004 Aug;119(2):145-50
15158596
Surgery. 2003 Dec;134(6):964-71; discussion 971-2
14668729
J Cancer Res Clin Oncol. 2003 Mar;129(3):192-8
12684893
Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):332-8
12613443
Ann Surg. 2003 Jan;237(1):74-85
12496533
CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26
12568441
J Virol Methods. 2002 Sep;105(2):253-63
12270658
Mod Pathol. 2003 May;16(5):403-10
12748245
Anal Biochem. 2003 Apr 1;315(1):95-105
12672417
World J Gastroenterol. 2003 Aug;9(8):1819-23
12918128
Zhonghua Yi Xue Za Zhi. 2004 Feb 2;84(3):214-8
15059537
Eur J Cancer. 2004 Mar;40(4):549-58
14962722
Oncol Rep. 2004 Apr;11(4):825-31
15010880
Cancer. 1998 Oct 1;83(7):1328-34
9762933
Int J Mol Med. 2003 Feb;11(2):217-21
12525881
Oncol Rep. 2003 Jul-Aug;10(4):963-6
12792753
J Med Virol. 2004 Feb;72(2):312-9
14695676
Am J Gastroenterol. 2000 Aug;95(8):1939-45
10950039
Pathol Int. 2003 May;53(5):265-9
12713559
N Engl J Med. 2004 Mar 18;350(12):1200-10
15028824
Am J Surg Pathol. 2002 Aug;26(8):989-97
12170085
Hum Pathol. 2004 May;35(5):576-81
15138932